 Randall Meacham
Concepts (361)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Infertility, Male | 13 | 2013 | 59 | 1.910 |
Why?
| | Ejaculation | 6 | 2006 | 11 | 1.090 |
Why?
| | Testis | 8 | 2012 | 133 | 1.020 |
Why?
| | Spermatozoa | 5 | 2007 | 84 | 0.950 |
Why?
| | Varicocele | 7 | 2011 | 10 | 0.940 |
Why?
| | Prostatic Neoplasms | 14 | 2012 | 925 | 0.820 |
Why?
| | Oligospermia | 5 | 2013 | 8 | 0.730 |
Why?
| | Azoospermia | 3 | 2013 | 5 | 0.680 |
Why?
| | Reproduction | 3 | 2006 | 181 | 0.530 |
Why?
| | Sperm Count | 5 | 2004 | 16 | 0.510 |
Why?
| | Urology | 3 | 2019 | 46 | 0.480 |
Why?
| | Hypogonadism | 3 | 2013 | 75 | 0.470 |
Why?
| | Penis | 3 | 2012 | 37 | 0.460 |
Why?
| | Clomiphene | 1 | 2013 | 15 | 0.440 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2013 | 26 | 0.440 |
Why?
| | Male | 57 | 2021 | 55579 | 0.410 |
Why?
| | Erectile Dysfunction | 3 | 2012 | 38 | 0.390 |
Why?
| | Testosterone | 3 | 2013 | 343 | 0.380 |
Why?
| | Diphosphonates | 1 | 2011 | 51 | 0.380 |
Why?
| | Fertility | 2 | 2006 | 130 | 0.350 |
Why?
| | Apoptosis | 3 | 2004 | 2369 | 0.350 |
Why?
| | Oxalates | 4 | 2012 | 10 | 0.350 |
Why?
| | Testicular Neoplasms | 3 | 2006 | 97 | 0.340 |
Why?
| | Vas Deferens | 2 | 2006 | 15 | 0.330 |
Why?
| | Ejaculatory Ducts | 4 | 2005 | 4 | 0.330 |
Why?
| | Evidence-Based Medicine | 1 | 2013 | 667 | 0.320 |
Why?
| | Electric Stimulation | 3 | 2005 | 252 | 0.320 |
Why?
| | Genetic Therapy | 2 | 2008 | 257 | 0.320 |
Why?
| | Urinary Bladder | 3 | 2019 | 164 | 0.320 |
Why?
| | Potassium Channels, Tandem Pore Domain | 2 | 2019 | 12 | 0.310 |
Why?
| | Autonomic Dysreflexia | 1 | 2007 | 4 | 0.290 |
Why?
| | Prostate | 1 | 2008 | 156 | 0.290 |
Why?
| | Spermatogenesis | 4 | 2002 | 52 | 0.290 |
Why?
| | Antineoplastic Agents | 2 | 2011 | 1895 | 0.290 |
Why?
| | Vibration | 1 | 2007 | 58 | 0.290 |
Why?
| | Physical Stimulation | 1 | 2007 | 77 | 0.280 |
Why?
| | Humans | 63 | 2022 | 114757 | 0.280 |
Why?
| | Perineum | 1 | 2006 | 25 | 0.280 |
Why?
| | Penile Induration | 1 | 2006 | 2 | 0.270 |
Why?
| | Vasovasostomy | 1 | 2006 | 1 | 0.270 |
Why?
| | Inguinal Canal | 1 | 2006 | 7 | 0.270 |
Why?
| | Genital Diseases, Male | 2 | 1996 | 15 | 0.260 |
Why?
| | Semen Preservation | 2 | 2004 | 3 | 0.260 |
Why?
| | Semen | 3 | 2002 | 18 | 0.260 |
Why?
| | Health Expenditures | 1 | 2007 | 171 | 0.260 |
Why?
| | Calcium Channel Blockers | 1 | 2006 | 115 | 0.250 |
Why?
| | Cost of Illness | 1 | 2007 | 254 | 0.250 |
Why?
| | Anal Canal | 1 | 2005 | 83 | 0.240 |
Why?
| | Interferon-alpha | 1 | 2006 | 187 | 0.240 |
Why?
| | Aging | 5 | 2013 | 1620 | 0.240 |
Why?
| | Spinal Cord Injuries | 1 | 2007 | 172 | 0.230 |
Why?
| | Cloning, Organism | 1 | 2004 | 6 | 0.230 |
Why?
| | Bioethical Issues | 1 | 2004 | 8 | 0.230 |
Why?
| | Cryptorchidism | 1 | 2004 | 12 | 0.230 |
Why?
| | Psychology, Adolescent | 1 | 2004 | 63 | 0.230 |
Why?
| | Pain Management | 1 | 2006 | 289 | 0.220 |
Why?
| | Vasectomy | 1 | 2003 | 1 | 0.220 |
Why?
| | Tissue and Organ Harvesting | 1 | 2003 | 62 | 0.220 |
Why?
| | Matrix Metalloproteinase 9 | 4 | 2012 | 119 | 0.210 |
Why?
| | Epithelial Cells | 5 | 2012 | 955 | 0.210 |
Why?
| | Sperm Motility | 3 | 1998 | 26 | 0.210 |
Why?
| | Sexual Dysfunctions, Psychological | 1 | 2003 | 31 | 0.210 |
Why?
| | Cryopreservation | 2 | 2004 | 92 | 0.200 |
Why?
| | Kidney Medulla | 3 | 2008 | 29 | 0.200 |
Why?
| | Proto-Oncogene Proteins c-ets | 2 | 2012 | 51 | 0.190 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2002 | 511 | 0.180 |
Why?
| | Checklist | 1 | 2021 | 83 | 0.180 |
Why?
| | Operating Rooms | 1 | 2021 | 87 | 0.180 |
Why?
| | Inflammation | 1 | 2010 | 2481 | 0.180 |
Why?
| | Interdisciplinary Communication | 1 | 2021 | 182 | 0.180 |
Why?
| | Cysts | 3 | 1995 | 93 | 0.170 |
Why?
| | Kidney Tubules, Proximal | 2 | 2012 | 113 | 0.170 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 27 | 0.160 |
Why?
| | Hormone Replacement Therapy | 2 | 2013 | 77 | 0.160 |
Why?
| | Urination | 1 | 2019 | 41 | 0.160 |
Why?
| | Adult | 17 | 2022 | 30548 | 0.160 |
Why?
| | Nephrectomy | 1 | 2019 | 149 | 0.160 |
Why?
| | Patient Care Team | 2 | 2021 | 517 | 0.160 |
Why?
| | Cell Survival | 4 | 2011 | 1021 | 0.160 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 2 | 2010 | 262 | 0.150 |
Why?
| | Patient Safety | 1 | 2021 | 278 | 0.150 |
Why?
| | General Surgery | 1 | 2019 | 126 | 0.150 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2011 | 196 | 0.150 |
Why?
| | Priapism | 1 | 1998 | 10 | 0.150 |
Why?
| | Administration, Intravesical | 1 | 2017 | 14 | 0.150 |
Why?
| | Cell Line, Tumor | 8 | 2012 | 2725 | 0.150 |
Why?
| | Neoplasm Invasiveness | 4 | 2012 | 445 | 0.150 |
Why?
| | Specimen Handling | 1 | 1998 | 156 | 0.150 |
Why?
| | Urethra | 1 | 2017 | 48 | 0.140 |
Why?
| | Animals | 15 | 2019 | 31762 | 0.140 |
Why?
| | Urinary Bladder, Overactive | 1 | 2017 | 20 | 0.140 |
Why?
| | Kidney Tubules, Collecting | 2 | 2008 | 25 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 227 | 0.140 |
Why?
| | Internship and Residency | 2 | 2019 | 932 | 0.140 |
Why?
| | Computer Communication Networks | 1 | 1996 | 32 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 3 | 2008 | 146 | 0.130 |
Why?
| | Muscle Contraction | 1 | 2019 | 388 | 0.130 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 3 | 2008 | 164 | 0.130 |
Why?
| | Temperature | 1 | 1998 | 575 | 0.130 |
Why?
| | Cannabinoids | 1 | 2017 | 115 | 0.130 |
Why?
| | Opioid-Related Disorders | 1 | 2022 | 413 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2022 | 773 | 0.120 |
Why?
| | Microsurgery | 2 | 2005 | 59 | 0.120 |
Why?
| | Marijuana Use | 1 | 2017 | 167 | 0.120 |
Why?
| | Drug Synergism | 2 | 2011 | 316 | 0.110 |
Why?
| | Asthenozoospermia | 1 | 2013 | 1 | 0.110 |
Why?
| | Rats, Sprague-Dawley | 4 | 2012 | 2209 | 0.110 |
Why?
| | Imidazoles | 2 | 2011 | 211 | 0.110 |
Why?
| | Hyperoxaluria | 1 | 2012 | 3 | 0.100 |
Why?
| | Rats | 5 | 2012 | 4943 | 0.100 |
Why?
| | Radiation-Protective Agents | 1 | 2012 | 26 | 0.100 |
Why?
| | Receptors, Virus | 1 | 2012 | 75 | 0.100 |
Why?
| | Metalloporphyrins | 1 | 2012 | 104 | 0.100 |
Why?
| | Pediatrics | 1 | 2019 | 983 | 0.100 |
Why?
| | Reproductive Techniques | 1 | 1991 | 6 | 0.100 |
Why?
| | Mitomycin | 1 | 2011 | 27 | 0.100 |
Why?
| | Valproic Acid | 1 | 2011 | 43 | 0.100 |
Why?
| | Radiotherapy | 1 | 2012 | 176 | 0.100 |
Why?
| | Osteoclasts | 1 | 2011 | 34 | 0.100 |
Why?
| | Cell Adhesion Molecules | 1 | 2012 | 168 | 0.100 |
Why?
| | Carcinoma, Transitional Cell | 1 | 2011 | 53 | 0.090 |
Why?
| | Laparoscopy | 2 | 2006 | 388 | 0.090 |
Why?
| | Resistance Training | 1 | 2013 | 113 | 0.090 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2011 | 109 | 0.090 |
Why?
| | Bone Resorption | 1 | 2011 | 73 | 0.090 |
Why?
| | Cell Hypoxia | 2 | 2009 | 220 | 0.090 |
Why?
| | Diabetes Complications | 2 | 2006 | 211 | 0.090 |
Why?
| | Constriction, Pathologic | 3 | 2005 | 208 | 0.090 |
Why?
| | Patient Care Management | 1 | 2011 | 53 | 0.090 |
Why?
| | Cell Movement | 2 | 2012 | 867 | 0.090 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 249 | 0.090 |
Why?
| | Androgens | 2 | 2009 | 167 | 0.090 |
Why?
| | Atrophy | 1 | 2010 | 152 | 0.090 |
Why?
| | Membrane Glycoproteins | 1 | 2012 | 429 | 0.090 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2011 | 198 | 0.090 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2010 | 57 | 0.090 |
Why?
| | Neoplasm Seeding | 1 | 1989 | 7 | 0.080 |
Why?
| | Neovascularization, Pathologic | 1 | 2011 | 283 | 0.080 |
Why?
| | Up-Regulation | 1 | 2012 | 812 | 0.080 |
Why?
| | Transfection | 2 | 2010 | 870 | 0.080 |
Why?
| | Bone Neoplasms | 1 | 2011 | 194 | 0.080 |
Why?
| | Prostatectomy | 1 | 1989 | 98 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 1989 | 181 | 0.080 |
Why?
| | Antioxidants | 1 | 2012 | 530 | 0.080 |
Why?
| | Continuity of Patient Care | 1 | 2011 | 254 | 0.080 |
Why?
| | Bone and Bones | 1 | 2011 | 278 | 0.080 |
Why?
| | Focal Adhesion Protein-Tyrosine Kinases | 1 | 2008 | 27 | 0.080 |
Why?
| | Biopsy | 1 | 1992 | 1040 | 0.080 |
Why?
| | Prostatic Hyperplasia | 1 | 2008 | 38 | 0.080 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 536 | 0.080 |
Why?
| | Patient Selection | 1 | 2011 | 641 | 0.080 |
Why?
| | Ultrasonography | 4 | 1995 | 629 | 0.070 |
Why?
| | Bone Density | 1 | 2011 | 432 | 0.070 |
Why?
| | Clinical Trials as Topic | 2 | 2011 | 935 | 0.070 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2008 | 61 | 0.070 |
Why?
| | Biomarkers | 1 | 2017 | 3416 | 0.070 |
Why?
| | Oxidative Stress | 2 | 2010 | 1084 | 0.070 |
Why?
| | Intracellular Signaling Peptides and Proteins | 1 | 2010 | 386 | 0.070 |
Why?
| | Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2009 | 249 | 0.070 |
Why?
| | Software | 1 | 2011 | 536 | 0.070 |
Why?
| | Reproductive Techniques, Assisted | 1 | 2007 | 32 | 0.070 |
Why?
| | Computer Simulation | 1 | 2011 | 878 | 0.070 |
Why?
| | Carcinoma in Situ | 1 | 2006 | 44 | 0.070 |
Why?
| | Cell Line | 5 | 2012 | 2639 | 0.070 |
Why?
| | Acupuncture Therapy | 1 | 2006 | 18 | 0.070 |
Why?
| | Injections, Intralesional | 1 | 2006 | 32 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2011 | 1214 | 0.070 |
Why?
| | Colonic Neoplasms | 1 | 1988 | 221 | 0.070 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1521 | 0.070 |
Why?
| | Health Resources | 1 | 2007 | 122 | 0.060 |
Why?
| | Hernia, Inguinal | 1 | 2006 | 27 | 0.060 |
Why?
| | Incidence | 2 | 2007 | 2312 | 0.060 |
Why?
| | Gene Expression Regulation | 2 | 2012 | 2321 | 0.060 |
Why?
| | Anastomosis, Surgical | 1 | 2006 | 136 | 0.060 |
Why?
| | Kidney | 1 | 2012 | 1184 | 0.060 |
Why?
| | Cell Culture Techniques | 1 | 2008 | 343 | 0.060 |
Why?
| | Anus, Imperforate | 1 | 2005 | 22 | 0.060 |
Why?
| | Sodium Chloride | 1 | 2006 | 136 | 0.060 |
Why?
| | Female | 9 | 2021 | 59507 | 0.060 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2008 | 498 | 0.060 |
Why?
| | Oxalic Acid | 1 | 2004 | 4 | 0.060 |
Why?
| | Middle Aged | 7 | 2007 | 26757 | 0.060 |
Why?
| | Signal Transduction | 3 | 2012 | 4522 | 0.060 |
Why?
| | Hypoxia | 1 | 2010 | 957 | 0.060 |
Why?
| | Rupture | 1 | 2004 | 95 | 0.060 |
Why?
| | Sexual Dysfunction, Physiological | 1 | 2005 | 60 | 0.060 |
Why?
| | Seminiferous Tubules | 1 | 2004 | 10 | 0.060 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2003 | 7 | 0.060 |
Why?
| | Andrology | 1 | 2003 | 1 | 0.060 |
Why?
| | Ambulatory Care | 1 | 2007 | 479 | 0.050 |
Why?
| | Sex Counseling | 1 | 2003 | 4 | 0.050 |
Why?
| | Recombinant Proteins | 1 | 2006 | 1233 | 0.050 |
Why?
| | Down-Regulation | 2 | 2017 | 596 | 0.050 |
Why?
| | Adenocarcinoma | 1 | 1988 | 801 | 0.050 |
Why?
| | Aged | 6 | 2013 | 19094 | 0.050 |
Why?
| | Adolescent | 4 | 2007 | 17808 | 0.050 |
Why?
| | RNA, Small Interfering | 2 | 2017 | 543 | 0.050 |
Why?
| | Phenotype | 4 | 2010 | 2812 | 0.050 |
Why?
| | Pain | 1 | 2006 | 710 | 0.050 |
Why?
| | Interleukin-6 | 1 | 2004 | 675 | 0.050 |
Why?
| | Pain, Postoperative | 1 | 2022 | 191 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2007 | 6350 | 0.050 |
Why?
| | Counseling | 1 | 2003 | 342 | 0.040 |
Why?
| | Organizational Culture | 1 | 2021 | 119 | 0.040 |
Why?
| | Alcoholism | 1 | 2006 | 714 | 0.040 |
Why?
| | Mice | 5 | 2019 | 14916 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2011 | 1868 | 0.040 |
Why?
| | Sexual Behavior | 2 | 1994 | 440 | 0.040 |
Why?
| | Accreditation | 1 | 2019 | 76 | 0.040 |
Why?
| | Cell Growth Processes | 2 | 2010 | 51 | 0.040 |
Why?
| | Mice, Inbred C57BL | 2 | 2019 | 4710 | 0.040 |
Why?
| | Cell Count | 2 | 2005 | 305 | 0.040 |
Why?
| | RNA, Messenger | 3 | 2012 | 2557 | 0.040 |
Why?
| | Hospitalization | 1 | 2007 | 1752 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2022 | 490 | 0.040 |
Why?
| | DNA Replication | 2 | 2004 | 205 | 0.040 |
Why?
| | United States | 2 | 2019 | 12176 | 0.040 |
Why?
| | Caveolins | 1 | 2017 | 5 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2012 | 1635 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2011 | 12515 | 0.040 |
Why?
| | DNA Primers | 2 | 2010 | 514 | 0.030 |
Why?
| | Blotting, Western | 2 | 2010 | 1151 | 0.030 |
Why?
| | Seminal Vesicles | 1 | 1995 | 8 | 0.030 |
Why?
| | Mullerian Ducts | 1 | 1995 | 8 | 0.030 |
Why?
| | Prostatic Diseases | 1 | 1995 | 4 | 0.030 |
Why?
| | Cytoskeleton | 1 | 2017 | 177 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 1998 | 424 | 0.030 |
Why?
| | Arteries | 1 | 1998 | 247 | 0.030 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 370 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 348 | 0.030 |
Why?
| | International Cooperation | 1 | 1996 | 172 | 0.030 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 4625 | 0.030 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2017 | 235 | 0.030 |
Why?
| | Skin | 2 | 2012 | 659 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2005 | 5035 | 0.030 |
Why?
| | Paternal Age | 1 | 1994 | 2 | 0.030 |
Why?
| | Climacteric | 1 | 1994 | 4 | 0.030 |
Why?
| | Rectum | 1 | 1995 | 153 | 0.030 |
Why?
| | Chromosome Disorders | 1 | 1994 | 35 | 0.030 |
Why?
| | Diverticulum | 1 | 1994 | 11 | 0.030 |
Why?
| | Practice Patterns, Physicians' | 1 | 2022 | 1178 | 0.030 |
Why?
| | Color | 1 | 1994 | 74 | 0.030 |
Why?
| | Urethral Diseases | 1 | 1994 | 18 | 0.030 |
Why?
| | Chromosome Aberrations | 1 | 1994 | 138 | 0.030 |
Why?
| | Base Sequence | 2 | 2010 | 2118 | 0.030 |
Why?
| | Quality Improvement | 1 | 2021 | 951 | 0.030 |
Why?
| | Lost to Follow-Up | 1 | 2013 | 22 | 0.030 |
Why?
| | Leydig Cells | 1 | 1993 | 11 | 0.030 |
Why?
| | Sex Hormone-Binding Globulin | 1 | 2013 | 48 | 0.030 |
Why?
| | Gonadotropins, Pituitary | 1 | 1993 | 22 | 0.030 |
Why?
| | Sertoli Cells | 1 | 1993 | 21 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 1994 | 494 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2019 | 2582 | 0.030 |
Why?
| | Gene Expression | 2 | 2008 | 1420 | 0.030 |
Why?
| | Physical Examination | 1 | 1994 | 220 | 0.030 |
Why?
| | Pilot Projects | 1 | 2017 | 1370 | 0.030 |
Why?
| | Patient Dropouts | 1 | 2013 | 66 | 0.030 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2012 | 35 | 0.030 |
Why?
| | Sex Chromosome Aberrations | 1 | 1993 | 51 | 0.030 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 23 | 0.030 |
Why?
| | Radiation, Ionizing | 1 | 2012 | 72 | 0.030 |
Why?
| | Crystallization | 1 | 2012 | 136 | 0.030 |
Why?
| | Upper Extremity | 1 | 2013 | 84 | 0.030 |
Why?
| | Transplantation, Heterologous | 1 | 2012 | 183 | 0.020 |
Why?
| | Neoplasm Transplantation | 1 | 2012 | 232 | 0.020 |
Why?
| | Insemination, Artificial | 1 | 1991 | 12 | 0.020 |
Why?
| | Kidney Tubules | 1 | 2012 | 107 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 843 | 0.020 |
Why?
| | Diagnosis, Differential | 1 | 1995 | 1340 | 0.020 |
Why?
| | Rats, Wistar | 1 | 2012 | 368 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 2013 | 176 | 0.020 |
Why?
| | Menopause | 1 | 1994 | 271 | 0.020 |
Why?
| | Fertilization in Vitro | 1 | 1991 | 71 | 0.020 |
Why?
| | Cluster Analysis | 1 | 2012 | 460 | 0.020 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2012 | 271 | 0.020 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2012 | 168 | 0.020 |
Why?
| | Mice, Nude | 1 | 2012 | 635 | 0.020 |
Why?
| | Efficiency | 1 | 2011 | 84 | 0.020 |
Why?
| | Muscle Strength | 1 | 2013 | 270 | 0.020 |
Why?
| | Activities of Daily Living | 1 | 2013 | 350 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2012 | 528 | 0.020 |
Why?
| | DNA Damage | 1 | 2012 | 357 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2013 | 1122 | 0.020 |
Why?
| | Workload | 1 | 2011 | 132 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 797 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2011 | 854 | 0.020 |
Why?
| | Actuarial Analysis | 1 | 1989 | 21 | 0.020 |
Why?
| | Radiotherapy, High-Energy | 1 | 1989 | 12 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 1994 | 1796 | 0.020 |
Why?
| | Body Composition | 1 | 2013 | 592 | 0.020 |
Why?
| | Safety | 1 | 2011 | 297 | 0.020 |
Why?
| | Patient Compliance | 1 | 2013 | 525 | 0.020 |
Why?
| | Risk Factors | 2 | 1994 | 8627 | 0.020 |
Why?
| | Tumor Stem Cell Assay | 1 | 2008 | 33 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2013 | 1846 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2011 | 954 | 0.020 |
Why?
| | Brachytherapy | 1 | 1989 | 104 | 0.020 |
Why?
| | Anoikis | 1 | 2008 | 31 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 1989 | 280 | 0.020 |
Why?
| | Statistics as Topic | 1 | 1989 | 294 | 0.020 |
Why?
| | Glyceraldehyde 3-Phosphate Dehydrogenase (NADP+) | 1 | 2008 | 8 | 0.020 |
Why?
| | Penile Erection | 1 | 2008 | 6 | 0.020 |
Why?
| | Genes, Immediate-Early | 1 | 2008 | 15 | 0.020 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2008 | 55 | 0.020 |
Why?
| | Prevalence | 1 | 1994 | 2249 | 0.020 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 928 | 0.020 |
Why?
| | Culture Media | 1 | 2008 | 155 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 2008 | 173 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2008 | 47 | 0.020 |
Why?
| | NADPH Oxidases | 1 | 2008 | 120 | 0.020 |
Why?
| | Kidney Calculi | 1 | 1988 | 30 | 0.020 |
Why?
| | Ureter | 1 | 1988 | 31 | 0.020 |
Why?
| | Lithotripsy | 1 | 1988 | 40 | 0.020 |
Why?
| | Catheters, Indwelling | 1 | 1988 | 79 | 0.020 |
Why?
| | Cyclooxygenase 2 | 1 | 2008 | 164 | 0.020 |
Why?
| | Superoxides | 1 | 2008 | 214 | 0.020 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2012 | 1147 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-myc | 1 | 2008 | 115 | 0.020 |
Why?
| | Regression Analysis | 1 | 1989 | 946 | 0.020 |
Why?
| | MAP Kinase Signaling System | 1 | 2008 | 276 | 0.020 |
Why?
| | Genetic Vectors | 1 | 2008 | 291 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2008 | 787 | 0.020 |
Why?
| | Cell Adhesion | 1 | 2008 | 430 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2008 | 287 | 0.020 |
Why?
| | Pyridines | 1 | 2010 | 425 | 0.020 |
Why?
| | Transcription, Genetic | 1 | 2012 | 1316 | 0.020 |
Why?
| | Models, Animal | 1 | 2008 | 345 | 0.020 |
Why?
| | Research Design | 1 | 2011 | 931 | 0.020 |
Why?
| | Diabetic Angiopathies | 1 | 2008 | 244 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2013 | 2539 | 0.020 |
Why?
| | Swine | 1 | 2008 | 700 | 0.020 |
Why?
| | Models, Biological | 1 | 2012 | 1630 | 0.020 |
Why?
| | Pregnancy | 2 | 1997 | 5525 | 0.020 |
Why?
| | Cell Cycle | 1 | 2008 | 543 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 994 | 0.020 |
Why?
| | Testicular Hydrocele | 1 | 2004 | 1 | 0.010 |
Why?
| | Transcription Factors | 1 | 2012 | 1528 | 0.010 |
Why?
| | Drug Monitoring | 1 | 2006 | 184 | 0.010 |
Why?
| | Algorithms | 1 | 2011 | 1468 | 0.010 |
Why?
| | Ligation | 1 | 2004 | 75 | 0.010 |
Why?
| | Urinary Retention | 1 | 2004 | 19 | 0.010 |
Why?
| | Carcinoma | 1 | 1986 | 198 | 0.010 |
Why?
| | Phosphorylation | 1 | 2008 | 1571 | 0.010 |
Why?
| | Prognosis | 2 | 1989 | 3334 | 0.010 |
Why?
| | Veins | 1 | 2004 | 55 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2011 | 2763 | 0.010 |
Why?
| | Hospital Costs | 1 | 2004 | 103 | 0.010 |
Why?
| | Treatment Outcome | 2 | 2008 | 9089 | 0.010 |
Why?
| | Cardiovascular Diseases | 1 | 2013 | 1727 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2196 | 0.010 |
Why?
| | Diabetes Mellitus | 1 | 2008 | 904 | 0.010 |
Why?
| | Time Factors | 1 | 1989 | 6124 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2005 | 3890 | 0.010 |
Why?
| | Ultrasonography, Doppler, Color | 1 | 1994 | 33 | 0.010 |
Why?
| | Postoperative Complications | 1 | 2004 | 2127 | 0.010 |
Why?
| | Calcinosis | 1 | 1992 | 242 | 0.010 |
Why?
| | Silicones | 1 | 1988 | 20 | 0.000 |
Why?
| | Urinary Catheterization | 1 | 1988 | 23 | 0.000 |
Why?
| | Ureteral Obstruction | 1 | 1988 | 54 | 0.000 |
Why?
| | Child | 1 | 2004 | 18352 | 0.000 |
Why?
| | Neoplasm Recurrence, Local | 1 | 1986 | 863 | 0.000 |
Why?
|
|
Meacham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|